233 related articles for article (PubMed ID: 14642487)
1. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
[TBL] [Abstract][Full Text] [Related]
2. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
3. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.
Bart J; Dijkers EC; Wegman TD; de Vries EG; van der Graaf WT; Groen HJ; Vaalburg W; Willemsen AT; Hendrikse NH
Br J Pharmacol; 2005 Aug; 145(8):1045-51. PubMed ID: 15951832
[TBL] [Abstract][Full Text] [Related]
4. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
[TBL] [Abstract][Full Text] [Related]
5. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
[TBL] [Abstract][Full Text] [Related]
6. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
[TBL] [Abstract][Full Text] [Related]
7. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
8. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
9. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
[TBL] [Abstract][Full Text] [Related]
10. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
Takashima T; Yokoyama C; Mizuma H; Yamanaka H; Wada Y; Onoe K; Nagata H; Tazawa S; Doi H; Takahashi K; Morita M; Kanai M; Shibasaki M; Kusuhara H; Sugiyama Y; Onoe H; Watanabe Y
J Nucl Med; 2011 Jun; 52(6):950-7. PubMed ID: 21571790
[TBL] [Abstract][Full Text] [Related]
11. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET.
Bauer M; Karch R; Neumann F; Abrahim A; Wagner CC; Kletter K; Müller M; Zeitlinger M; Langer O
Eur J Clin Pharmacol; 2009 Sep; 65(9):941-6. PubMed ID: 19655132
[TBL] [Abstract][Full Text] [Related]
12. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Modeling of (
García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
[TBL] [Abstract][Full Text] [Related]
14. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
[TBL] [Abstract][Full Text] [Related]
15. Quantification of P-glycoprotein function at the human blood-brain barrier using [
Mossel P; Arif WM; De Souza GS; Varela LG; van der Weijden CWJ; Boersma HH; Willemsen ATM; Boellaard R; Elsinga PH; Borra RJH; Dierckx RAJO; Lammertsma AA; Bartels AL; Luurtsema G
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3917-3927. PubMed ID: 37552369
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
[TBL] [Abstract][Full Text] [Related]
17. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.
Bauer M; Karch R; Neumann F; Wagner CC; Kletter K; Müller M; Löscher W; Zeitlinger M; Langer O
J Cereb Blood Flow Metab; 2010 Mar; 30(3):510-5. PubMed ID: 20010957
[TBL] [Abstract][Full Text] [Related]
18. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
19. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
20. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
